TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04784247

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: 20mg daily (two 10mg lenvatinib capsules) taken orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: 20mg daily (two 10mg lenvatinib capsules) taken orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: 20mg daily (two 10mg lenvatinib capsules) taken orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: 20mg daily (two 10mg lenvatinib capsules) taken orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: 20mg daily (two 10mg lenvatinib capsules) taken orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: (200mg) will be administered as a 30-minute IV infusion, Q3W +/-3 days (infusions lasting between 25-40 minutes. Study treatment with pembrolizumab may be administered up to 3 days before or after the scheduled Day 1 of each cycle due to administrative reasons.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: (200mg) will be administered as a 30-minute IV infusion, Q3W +/-3 days (infusions lasting between 25-40 minutes. Study treatment with pembrolizumab may be administered up to 3 days before or after the scheduled Day 1 of each cycle due to administrative reasons.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: (200mg) will be administered as a 30-minute IV infusion, Q3W +/-3 days (infusions lasting between 25-40 minutes. Study treatment with pembrolizumab may be administered up to 3 days before or after the scheduled Day 1 of each cycle due to administrative reasons.
Study: NCT05225506

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Exercise sessions will be one hour in duration and be a combination of resistance, aerobic, and balance exercise, with emphasis on movements specifically targeting common deficits seen in Parkinson's.
Study: NCT05750485

Intervention type: OTHER
Intervention: Pupilometric evaluation
Description: Pupilometric evaluation under procedural sedation with propofol
Study: NCT04784247

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: (200mg) will be administered as a 30-minute IV infusion, Q3W +/-3 days (infusions lasting between 25-40 minutes. Study treatment with pembrolizumab may be administered up to 3 days before or after the scheduled Day 1 of each cycle due to administrative reasons.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: (200mg) will be administered as a 30-minute IV infusion, Q3W +/-3 days (infusions lasting between 25-40 minutes. Study treatment with pembrolizumab may be administered up to 3 days before or after the scheduled Day 1 of each cycle due to administrative reasons.
Study: NCT06074419

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Occulus quest 2 virtual reality glasses
Description: Patients will be shown nature videos via the specified virtual reality connection.
Study: NCT06173336

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: gastric per-oral endoscopic myotomy (G-POEM)
Description: Comparing single versus double pyloromyotomy in G-POEM for refractory and severe gastroparesis.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: gastric per-oral endoscopic myotomy (G-POEM)
Description: Comparing single versus double pyloromyotomy in G-POEM for refractory and severe gastroparesis.
Study: NCT05987657

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Salivary and blood progesterone dosage
Description: Salivary dosage: patient will chew a dry swab for 2 minutes; when the swab is soaked it is put back in its small case and sent to the laboratory for analysis.~In parallel, the same patients will have a blood sample of 4 ml to dose blood progesterone on an EDTA tube. It will be also sent to the laboratory for analysis.~Both analyses will be done only once on triggering day meaning 36 hours before oocyte retrieval.
Study: NCT06273241

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: food intake
Description: A single dose of 1000 mg berberine in two capsules will be administered with 250 ml of still water in the overnight fasting condition as the control condition. The two intervention arms will test the effect of different meals on berberine kinetics. A total amount of 12 blood samples at defined time points (baseline; 1; 2; 3; 4; 5; 6; 7; 8; 24 h) will be taken. For glucose and insulin measurements, blood samples will be obtained at 4 h, 5 h and 6 h .

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: food intake
Description: A single dose of 1000 mg berberine in two capsules will be administered with 250 ml of still water in the overnight fasting condition as the control condition. The two intervention arms will test the effect of different meals on berberine kinetics. A total amount of 12 blood samples at defined time points (baseline; 1; 2; 3; 4; 5; 6; 7; 8; 24 h) will be taken. For glucose and insulin measurements, blood samples will be obtained at 4 h, 5 h and 6 h .

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: food intake
Description: A single dose of 1000 mg berberine in two capsules will be administered with 250 ml of still water in the overnight fasting condition as the control condition. The two intervention arms will test the effect of different meals on berberine kinetics. A total amount of 12 blood samples at defined time points (baseline; 1; 2; 3; 4; 5; 6; 7; 8; 24 h) will be taken. For glucose and insulin measurements, blood samples will be obtained at 4 h, 5 h and 6 h .
Study: NCT06469346

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nordic Hamstring Eccentric Exercise Training
Description: Warm up: stationary bycicle at 50 watts and 60 bpm Mobility exercises for hip and knee joint~Nordic eccentric exercise protocol:~* Week 1: 2 sets x 5 repetitions~* Week 2: 2 sets x 6 repetitions~* Week 3: 3 sets x 6 repetitions~* Week 4-6: 3 sets x 8 repetitions
Study: NCT04889755

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: SibACCESS
Description: The primary goal of the SibACCESS program is to increase siblings' exposure to and opportunity to process cancer-related cues to decrease onset or intensification of posttraumatic stress. The program is focused on siblings, with a brief parent education component. Parents will receive psychoeducation and brief skills training to support siblings enrolled in the program. Siblings will participate in 7 group sessions and one individual session in which they will learn skills and strategies to confront information about cancer and tolerate uncomfortable thoughts and feelings related to cancer, and thereby reduce avoidance of cancer-related emotions.
Study: NCT05212376

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Foot massage
Description: Foot massage is applied in the form of pressure, rubbing and stimulation with special hand and finger techniques to reflex - warning points corresponding to all regions, organs and systems in the body. It is applied by applying pressure to all reflex points in the area from the toes to the ankles.~In the study, a quiet and comfortable environment will be prepared at a room temperature of approximately 23-26 0C, and techniques that reveal the relaxing and calming effect of the massage will be selected. Thumb compression, slapping, patting, rubbing and squeezing movements are planned to be applied for a total of 20 minutes, 10 minutes on each foot, at the same time every day for 7 days.
Study: NCT06469346

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Passive Hamstring Static Stretching Training
Description: Warm up: stationary bycicle at 50 watts and 60 bpm Mobility exercises for hip and knee joint~* Week 1-2: 1 set x 2 repetitions of 30 seconds~* Week 3: 1 set x 3 repetitions of 30 seconds~* Week 4-6: 1 set x 3 reps of 40 seconds
Study: NCT05135429

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bathing
Description: The data of the study were obtained from premature newborns born at 34 weeks and above, who were hospitalized.
Study: NCT06469346

Intervention type: OTHER
Group type: OTHER
Intervention: Control Group
Description: No intervention
Study: NCT04869332

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: three cancellous screws
Description: All patients with femoral neck fractures will be randomly divided into 2 groups at a ratio of 1:1. Three screws for internal fixation in the three-screw group, and three cancellous screws with an inverted triangle pattern are used to fix the fracture of femoral neck.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: four cancellous screws
Description: All patients with femoral neck fractures will be randomly divided into 2 groups at a ratio of 1:1. Four screws for internal fixation in the four-screw group, and the fourth screw will be implanted in the horizontal direction of the femoral distance on the basis of the three screws.
Study: NCT05251090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADVATE
Description: 50 international units (IU)/kg, a single dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FRSW107
Description: 50 IU/kg, a single dose.
Study: NCT06062511

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ESIT12 D
Description: ESIT12 is a poplar-type propolis powder extract containing phenolic compounds from flavonoids and phenolic acids family. ESIT12 D contains 400 mg of ESIT12

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ESIT12 4D
Description: ESIT12 is a poplar-type propolis powder extract containing phenolic compounds from flavonoids and phenolic acids family. ESIT12 4D contains 1600 mg of ESIT12

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is composed of the carriers of ESIT12 : arabic gum, sucrose and silicon dioxide mix
Study: NCT06095583

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tifcemalimab injection
Description: 200mg once every 3weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: toripalimab injection
Description: 240mg once every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: toripalimab injection
Description: 240mg once every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Tifcemalimab
Description: every 3weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Tifcemalimab
Description: every 3weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for toripalimab
Description: every 3weeks
Study: NCT05434000

Intervention type: DRUG
Group type: OTHER
Intervention: Hydroxyurea
Description: Children at risk of developing stroke (TCD values\>200cm/s) will be given 20mg/kg of Hydroxyurea
Study: NCT05459272

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Aquilea Sueno Forte
Description: The test product consists of a dietary supplement in the form of tablets with three layers containing: melatonin (1.95 mg/tablet) and herbal products (extracts from Griffonia, Passiflora, California poppy, Valerian, Melissa).~Patients should take one tablet daily 30 min before go to bed during 7 days (from day 7 to day 14).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo will consist of tablets with three layers and with the same appearance as the dietary supplement under study, but containing no active ingredients.~Patients should take one tablet daily 30 min before go to bed during 7 days (from day 7 to day 14).
Study: NCT05912010

Intervention type: DIAGNOSTIC_TEST
Intervention: NP/OP swab
Description: NP/OP (nasopharyngeal/oropharyngeal) swabs will be collected from all cases at enrollment for respiratory pathogen multiplex PCR or pneumococcus culture.
Study: NCT04890561

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lemborexant
Description: Lemborexant oral tablets.
Study: NCT04955509

Intervention type: OTHER
Intervention: MRI
Description: conventional MRI and diffusion MRI

Intervention type: OTHER
Intervention: MRI
Description: conventional MRI and diffusion MRI
Study: NCT06021847

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ozonated water
Description: ozonated water was prepared with a concentration of (2-4 mg/l) ozone for 1 min. in a 25 mg of double distilled water 37o C employing an Ozone generator (Ozone generator type N 1888A, China.)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine mouthwash
Description: Commercial available chlorhexidine mouthwash in the market was used.
Study: NCT05326074

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Animal assisted therapy cohort
Description: A therapy dog will be present in the room during the routine outpatient psychiatric visit.
Study: NCT06240793

Intervention type: PROCEDURE
Group type: OTHER
Intervention: unilateral transforaminal epidural steroid block
Description: unilateral transforaminal epidural steroid block

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: bilateral transforaminal epidural steroid block
Description: bilateral transforaminal epidural steroid block
Study: NCT06244524

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High indoor CO2 exposure
Description: The participants will stay and sleep for eight hours in a closed bedroom.
Study: NCT05316519

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Transcutaneous Vagus Nerve Stimulation
Description: Visuomotor task training with transcutaneous stimulation targeting landmark that activates biomarker

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcutaneous Vagus Nerve Stimulation
Description: Visuomotor task training with transcutaneous stimulation targeting landmark that activates biomarker
Study: NCT06145204

Intervention type: OTHER
Intervention: questionnaire
Description: anamnesis, OMSPQ, DN4, Brief Pain Inventory-short form, lymph-ICF-LL
Study: NCT05845411

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful Eating
Description: Nutritional advice through expository content, group discussion, and exchange of experiences on self-knowledge, food awareness, and relationship with food and the body.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard dietary treatment
Description: Hypocaloric dietary prescription and nutritional education.
Study: NCT06002087

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unified Protocol for Transdiagnostic Treatment of Emotional Disorders
Description: The current researchers adapted the Unified Protocol (UP) treatment and used the adapted version in this study. UP outlines two complimentary modules for goal setting and psychoeducation followed by five core treatment modules: mindful emotion awareness, cognitive flexibility, countering emotional behaviors, awareness and tolerance of physical sensations, and emotion exposures, and an optional relapse prevention module to help people maintain their gains after treatment.
Study: NCT05483595

Intervention type: DRUG
Group type: OTHER
Intervention: Chinese herbal medicine FYTF-919
Description: Oral liquid 10ml

Intervention type: DRUG
Group type: OTHER
Intervention: Chinese herbal medicine FYTF-919
Description: Oral liquid 10ml
Study: NCT05712421

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: North Star
Description: North Star

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levothyroxine
Description: Levothyroxine
Study: NCT05263622

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Split-mouth administration for group B
Description: * Plaque disclosing agent application and instructions to patients for a correct oral hygiene;~* Airflow deplaquing with EMS handpiece (quadrants Q1 and Q3) and with Mectron handpiece (quadrants Q2 and Q4)~* Calculus removal with EMS ultrasound handpiece (Q1 and Q3) and with Mectron handpiece (Q2 and Q4)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Split-mouth administration for group A
Description: * Plaque disclosing agent application and instructions to patients for a correct oral hygiene;~* Airflow deplaquing with EMS handpiece (quadrants Q2 and Q4) and with Mectron handpiece (quadrants Q1 and Q3)~* Calculus removal with EMS ultrasound handpiece (Q2 and Q4) and with Mectron handpiece (Q1 and Q3)
Study: NCT06138236

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Collagen hydrolyzed peptides
Description: infiltration near the heal spur of 2ml of Arthrys
Study: NCT06291064

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide is given by intravenous (IV) infusion once every 3 weeks for 4 doses total (12 weeks). It will be given together with Epirubicin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: Epirubicin is given by intravenous (IV) infusion once every 3 weeks for 4 doses total (12 weeks). It will be given together with Cyclophosphamide.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel is given by intravenous (IV) infusion once every 3 weeks for 4 doses total (12 weeks). It will be given together with Carboplatin. Dosing will start after treatment with Epirubicin and Cyclophosphamide (EC) is completed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin is given by intravenous (IV) infusion once every 3 weeks for 4 doses total (12 weeks). It will be given together with Docetaxel. Dosing will start after treatment with EC is completed.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Breast Surgery
Description: Participants will undergo breast surgery after completing dosing with Carboplatin and Docetaxel to remove any remaining cancer in the breast.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine is a pill that will be taken by mouth daily for 6 months after surgery is completed.
Study: NCT06138236

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Collagen hydrolyzed peptides
Description: infiltration near the heal spur of 2ml of Arthrys

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Collagen hydrolyzed peptides
Description: infiltration near the heal spur of 2ml of Arthrys
Study: NCT06388967

Intervention type: DIAGNOSTIC_TEST
Intervention: PANcreatic cancer Exosome Early detectiON (PANXEON)
Description: This test will utilize quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) to quantify the expression levels of 5 cell-free and 8 exosome-miRNAs in plasma samples obtained from patients with pancreatic ductal adenocarcinoma and from individuals without it

Intervention type: DIAGNOSTIC_TEST
Intervention: PANcreatic cancer Exosome Early detectiON (PANXEON)
Description: This test will utilize quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) to quantify the expression levels of 5 cell-free and 8 exosome-miRNAs in plasma samples obtained from patients with pancreatic ductal adenocarcinoma and from individuals without it

Intervention type: DIAGNOSTIC_TEST
Intervention: PANcreatic cancer Exosome Early detectiON (PANXEON)
Description: This test will utilize quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) to quantify the expression levels of 5 cell-free and 8 exosome-miRNAs in plasma samples obtained from patients with pancreatic ductal adenocarcinoma and from individuals without it

Intervention type: DIAGNOSTIC_TEST
Intervention: PANcreatic cancer Exosome Early detectiON (PANXEON)
Description: This test will utilize quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) to quantify the expression levels of 5 cell-free and 8 exosome-miRNAs in plasma samples obtained from patients with pancreatic ductal adenocarcinoma and from individuals without it
Study: NCT05715983

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bascom II procedure
Description: Buttocks are strapped apart with wide adhesive tape. The area is prepared using antiseptic solution twice. Solution of brilliant green with 3% hydrogen peroxide was injected in all orifices to visualize all tracts and sinuses. The proposal area of incision is marked nearby sinus tract openings and the skin with lateralization on one side of the cleft. A vertical-orientated incision of the skin and subcutaneous fat around the primary and secondary orifices is made using a scalpel or a monopolar electrocautery. The sinus tract is excised in en-block till unchanged subcutaneous tissue. The wound is irrigated with antiseptic solution. If postoperative wound is larger than 5 cm then a silicone draining tube is placed through the contraperature in the upper corner. The wound is closed by interrupted sutures Vicryl/Polysorb 2/0 3/0 layer by layer. Aseptic dressing is applied to the closed wound.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SiLaC
Description: Buttocks are strapped apart with wide adhesive tape. The area is prepared using antiseptic solution twice. Solution of brilliant green with 3% hydrogen peroxide is injected in all orifices to visualize all tracts and sinuses. All visible orifices are excised with a scalpel or dermo punch. After that hairs are removed from the sinus by Volkmann curette. A metallic stylet is used to determine the length and direction of the different tracts. Then laser destruction of the sinus is performed with FiberLase VT laser, wavelength 1460 or 1520 nm, the laser energy 10-12 Watts. The fiber delivers energy homogeneously in a continuous way. Hemostasis by electrocautery. The wound is washed with povidone-iodine solution. Aseptic dressing is applied.
Study: NCT06506851

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AR-based Training with Microsoft HoloLens 2®
Description: Practical nurses in this group receive AR-based training using Microsoft HoloLens 2®. This training method incorporates augmented reality technology to provide immersive and interactive learning experiences, enhancing their proficiency in device utilization.